Effects of *Spirulina platensis* on insulin secretion, dipeptidyl peptidase IV activity and both carbohydrate digestion and absorption indicate potential as an adjunctive therapy for diabetes

**J. M. A. Hannan**, **Prawej Ansari**, **Shofiul Azam**, **Peter R. Flatt** and **Yasser H. A. Abdel Wahab**

1Department of Pharmacy, Independent University, Dhaka 1229, Bangladesh
2School of Biomedical Sciences, Ulster University, Co. Londonderry, Northern Ireland BT52 1SA, UK
3Department of Integrated Bioscience, Konkuk University, Chungiu 27478, Republic of Korea

Abstract

*Spirulina platensis* has been found to be useful in the treatment of type 2 diabetes. The present study aims to elucidate the effects of ethanol extract and butanol fraction of *S. platensis* on insulin release and glucose homoeostasis in type 2 diabetic rats, together with their mechanism of action. *In vitro* and *in vivo* methods were used including cellular studies to determine potential role of ion channels and cAMP in the inositolotropic actions of the extracts. The ethanol extract and butanol fraction stimulated insulin release from mouse islets and pancreatic β-cells in a concentration-dependent manner. The butanol fraction also similarly stimulated insulin release from perfused rat pancreas. The insulin-releasing action was augmented by glucose, isobutylmethylxanthine, tolbutamide and a depolarising concentration of KCl. The insulin secretory effect was attenuated with diazoxide and verapamil and by omission of extracellular Ca²⁺. Butanol fraction was found to significantly inhibit dipeptidyl peptidase IV enzyme activity. Moreover, butanol fraction improved glucose tolerance following oral glucose administration (2·5 g/kg body weight (b.w.)). The butanol fraction was tested on 24 h starved rats given an oral sucrose load (2·5 g/kg b.w.) to examine possible effects on carbohydrate digestion and absorption. *S. platensis* substantially decreased postprandial hyperglycaemia after oral sucrose load and increased unabsorbed sucrose content throughout the gut. During *in situ* intestinal perfusion with glucose, the butanol fraction reduced glucose absorption and promoted gut motility. Finally, chronic oral administration of butanol fraction for 28 d significantly decreased blood glucose, increased plasma insulin, pancreatic insulin stores, liver glycogen and improved lipid profile. The characterisation of active compounds from butanol fraction revealed the presence of *p*-coumaric acid, β-carotene, catechin and other antioxidant polyphenols. In conclusion, *S. platensis* could be an adjunctive therapy for the management of type 2 diabetes.

**Key words**: Diabetes; Plant therapies; Glucose; Insulin

Diabetes mellitus is a metabolic syndrome where pancreatic β-cells fail to meet the body’s need for insulin with resultant hyperglycaemia and increased risk of diabetic complications. The WHO recognised diabetes mellitus as the world’s fastest growing metabolic disorder. Type 1 diabetes is the result of total or near-total β-cell destruction, whereas type 2 diabetes mellitus (T2DM) is the result of β-cell dysfunction and insulin resistance. About 90 % of diabetic patients suffer from T2DM. This condition is associated with the alterations in the metabolism of lipids, carbohydrates and proteins(7), which causes multiple complications including CVD(9), retinopathy(3), neuropathy, cognitive decline(4), nephropathy and end-stage renal disease(9).

T2DM treatments include diet together with either a single or combination of oral anti-hyperglycaemic agents, to manage dysglycaemia(5,6). Although advances have been made recently in the treatment options to achieve better glycaemic control, they are often expensive and associated with notable adverse effects(7–9). This focuses attention particularly in poorer countries towards herbal therapy and dietary supplements as alternative approaches to the mainstream medical treatment of T2DM. Unlike contemporary treatment, herb-based medicines are entirely natural; they possess very few adverse effects and are generally affordable(9). It has been reported that nearly 30–76 % of T2DM patients from different countries are using herbal medicines(10,11) and that this approach is managing T2DM with safety(12).

Over the last decades, functional foods received attention as a potential source of useful bioactive protein hydrolysates.
and peptides that have health benefits and reduce the risk of disease\(^{13}\). In this way, many aquatic species have been studied with the generation of new and useful bioactive peptide sources. For instance, the eukaryotic microalgae and prokaryotic cyanobacteria (often called blue-green algae) utilisation in the food industry has become globally popular\(^{14,15}\). Edible microalgal and cyanobacterial proteins have been established as suitable precursors for the production of biologically active peptides\(^{14}\). Thus, a series of peptides isolated from microalgal or cyanobacterial hydrolysates have been demonstrated to exhibit desirable bioactivities, such as antioxidative, anticancer, anti-inflammatory and antihypertensive properties\(^{13,16-18}\).

*Spirulina platensis* is a unicellular cyanobacterium belonging to the Cyanophyceae class, Oscillatoriaceae family\(^{19}\). This organism (cyanobacterium) is characterised by spiral chains of the cells enclosed in a thin sheath. It contains very potent naturally occurring antioxidants and free radical scavenging agents\(^{20}\). *S. platensis* is non-toxic, bioavailable, and is believed to provide significant multiorgan protection against many drugs and chemically induced toxic assaults\(^{21}\). Active constituents exhibit anti-inflammatory, neuroprotective, hepatoprotective, immunomodulatory and anticancer activities\(^{22}\). A recent animal study reported potential anti-diabetic effects of *S. platensis*, but the mechanisms underlying such effects are unknown\(^{23-25}\). In this paper, we have made a detailed study of effects of *S. platensis* on pancreatic insulin release, dipeptidyl peptidase IV (DPP-IV) inhibition and various gastrointestinal (GI) tract actions to elucidate the mechanism and therapeutic potential of *S. platensis* for improvement of diabetes control.

### Materials and methods

#### Plant material and preparation of ethanol extract

*S. platensis* was purchased from Bangladesh Council of Scientific and Industrial Research, Dhaka, Bangladesh and was authenticated by a botanical taxonomist. A voucher specimen was deposited in the Bangladesh National Herbarium (Mirpur, Dhaka). The whole plants were dried at 40°C (oven) and processed into fine powder by a cyclotec grinding machine. The powder (2 kg) was extracted with 80% ethanol (10 litres) in a conical flask and put into an orbital shaker (550 rpm, 48–72 h). The extract was filtered using a Whatman filter paper, and ethanol was removed using a rotary evaporator (Fig. 1). A Varian 801 LY-3-TT freeze dryer (Varian) was used to freeze-dry the extract which was stored at 4°C until used.

---

![Fig. 1. Schematic diagram of preparation of ethanol extract and butanol partition fraction of *Spirulina platensis*.](image)
Preparation of butanol fraction of Spirulina platensis

According to the previously described method, the ethanol extract (50 g) was partitioned into hexane (0·5 litres × 3) and water (0·5 litres). Hexane fraction was separated, and soluble material (15 g) was isolated after evaporation to dryness. The water layer was additionally partitioned using 1-butanol (0·5 litres × 3), and soluble materials of 1-butanol (10·5 g) were obtained after evaporation to dryness. The latter watery portion was further concentrated using a rotary evaporator, and the end product was dried (20 g) using a freeze dryer and stored in a refrigerator at 4°C until used (Fig. 1). The ethanol extract and butanol fraction were analysed for bioactivity in the present studies.

Insulin secretion from isolated islets and β-cell lines

The effects of S. platensis on insulin release from BRIN-BD11 cells and isolated mouse islets were assessed as described previously. A range of concentrations of plant extract or butanol fraction or known modulators of insulin secretion were incubated with BRIN-BD11 cells in the presence or absence of 16·7 mM glucose for 60 min. Test incubations were performed in the presence of 16·7 mM glucose for 60 min. After incubation, the supernatants were collected and stored at –20°C until analysed by insulin radioimmunoassay.

Insulin secretion from perfused pancreas

Long-Evans male rats (180–250 g body weight (b.w.)) were anaesthetised with sodium-pentobarbital (50 mg/kg, intraperitoneal), and the pancreas was isolated and perfused at 37°C according to the method of Giroix et al. KRB buffer supplemented with 1·25 g/l bovine serum albumin and 40 g/l dextran T70 and 2·8- or 11·2-mu glucose. A mixture of O₂+CO₂ (95:5) was continuously used to gas the perfusate. The composition of the perfusate was changed after the first 20 min of equilibration as indicated in Fig. 3. Samples were stored at –20°C prior to measurement of insulin using ELISA kits supplied by Crystal Chem.

Membrane potential and intracellular calcium ([Ca²⁺]i)

The effects of S. platensis on membrane potential and intracellular Ca were measured using BRIN-BD11 cell monolayers as previously described. Cells were seeded onto ninety-six-well plates (black-walled, clear-bottomed microplates, Greiner) and washed with KRB buffer prior to the addition of FLEX assay reagents (Molecular Devices). Effects of introducing extract or butanol fraction and other reagents were monitored fluorometrically using Flex Station 3 (Molecular Devices) at wavelengths of 450 and 525 nm, respectively.

Dipeptidyl peptidase IV activity

Effects of S. platensis on DPP-IV enzyme activity were determined using a fluorometric method. Enzyme activity was determined using ninety-six-well black-walled, clear-bottomed microplates (Greiner) containing 8 mU/ml of DPP-IV enzyme and 200 μM of substrate (Gly-Pro-AMC) as described previously. Flex Station 3 (Molecular Devices) was used to measure the changes in fluorescence with an excitation and emission at 370 and 440 nm with 2·5 nm slit width, respectively.

Induction of experimental diabetes

Long-Evans male rats (150–200 g) were purchased from the International Center for Diarrheal Disease Research, Bangladesh. Standard environmental conditions with temperature of 22 ± 5°C, relative humidity of 55–65 % and 12 h light–12 h dark cycle were maintained. Food and fresh water were supplied ad libitum. The composition of the pelleted diet (metabolisable energy of 11·8 MJ/kg per 2820 kcal/kg) was described previously. T2DM was induced in neonatal rats at 2 d of age by a single intraperitoneal injection of streptozotocin (90 mg/kg b.w.). T2DM rats were selected for the experiments at 12 weeks of age after an oral glucose tolerance test. Animals exhibiting blood glucose levels of 8–12 mmol/l were chosen as type 2 diabetes rats. The ‘Principles of Laboratory Animals Care’ (National Institutes of Health Publication no. 86-23, revised 1985) and the UK Animals Scientific Procedures Act 1986 were followed.

Residual gut sucrose content

The effects of S. platensis on sucrose digestion and absorption from the GI tract were assessed after the oral administration of sucrose solution (2·5 g/kg b.w.) to 24-h fasted T2DM rats with or without butanol fraction of S. platensis (250 mg/kg, b.w.). Blood samples were collected from the tip of the tail prior to and after 30, 60, 120 and 240 min for glucose analysis. To measure the unabsorbed sucrose content of the GI tract, rats were killed at the same time points and the tract was excised and divided into six parts: the stomach, the upper (20 cm), middle and lower (20 cm) of the small intestine, the caecum and the large intestine. Each segment was washed with acidified ice-cold saline and centrifuged for 10 min at 3000 rpm (1000 g). The resulting supernatant was boiled for 2 h to hydrolyse the sucrose, and pH was adjusted (7·0–7·4) by adding NaOH. The concentration of serum glucose and the total amount of glucose liberated from GI tract were determined.

Intestinal glucose absorption

The effects of S. platensis on intestinal glucose absorption were determined using an in situ intestinal perfusion technique. Non-diabetic rats were fasted for 36 h followed by induction of anaesthesia with sodium pentobarbital (50 g/kg b.w.). Butanol fraction of S. platensis (5 mg/ml equal to 0·25 g/kg) dissolved in KRB buffer containing glucose (54 g/l) was infused via the rat pylori, and perfusate was collected at the end of ileum.
The control group was treated with KRB buffer only in the presence of glucose. Perfusion of intestine was carried out at a constant rate of 0·5 ml/min for 30 min at 37°C. The results were expressed as the percentage of glucose absorbed, measured from the amount of glucose in solution before and after the perfusion of intestine.

**Intestinal disaccharidase activity and gastrointestinal motility**

Intestinal disaccharidase enzyme activity was determined as described previously\(^{55}\). Non-diabetic rats were fasted for 20 h followed by the oral administration of *S. platensis* (250 mg/kg) or water alone. The rats were killed after 1 h, and the small intestine was collected, cut longitudinally and rinsed with ice-cold saline. Volume was made up to 10 ml by adding saline (0·9 % NaCl), and the tissue was homogenised. Aliquots of the homogenate were incubated at 37°C in a 40 ml sucrose solution for 60 min. Disaccharidase enzyme activity was measured as μmol/mg protein per h. Acarbose (200 mg/kg), an established disaccharidase enzyme inhibitor, was used as a control. GI motility was measured according to the method of Chatterjee\(^{56}\). The butanol fraction of *S. platensis* (250 mg/kg b.w.) or water (10 ml/kg) was administered orally to non-diabetic rats. One hour later, a suspension of BaSO\(_4\) milk (10 % BaSO\(_4\) and 0·5 % carboxymethyl cellulose; w/v) was administered orally to non-diabetic rats. Rats of both groups were killed after 15 min of administration of BaSO\(_4\). The length travelled by BaSO\(_4\) milk was calculated and expressed as the percentage of the total distance of the small intestine (pylorus to the ileo-caecal junction). The established drugs: Loperamide (5 mg/kg b.w.) and Sennoside (10 mg/kg b.w.) were used as positive controls.

**Glucose tolerance and chronic effects in type 2 diabetic rats**

The effects of butanol fraction of *S. platensis* on oral glucose tolerance were measured after fasting the T2DM rats for 12 h. Blood samples were obtained from the cut tip of the tail at given time points (0, 30, 60, 120 and 180 min) before and after oral administration of glucose (2·5 g/kg b.w.) with (Treated group) or without (Control group) *S. platensis* (250 mg/kg). The long-term effects of *S. platensis* on glucose homeostasis in T2DM rats were measured by twice daily administration (oral gavage) of butanol fraction (250 mg/kg) for 28 d. Control rats received oral administration of water alone. Blood samples were collected, and serum was separated by centrifugation and stored at −20°C until measurement of glucose, insulin and lipid profiles. Glucose and insulin were measured via the glucose oxidase–phenol amino phenazone (GOD-PAP) method (glucose kit, Randox™) and rat insulin ELISA Kit (Crystal Chem™), respectively.

**Effects of Spirulina platensis on liver glycogen content**

The effects of *Spirulina platensis* treatment for 28 d on liver glycogen content were determined as previously described\(^{37}\). Briefly, the weight of liver was measured and finely homogenised with 10 ml of 5 % trichloroacetic acid. The precipitated proteins were filtered, and glycogen content was analysed from the clear filtrate. One millilitre of the filtrate was mixed with 2 ml of 10 N KOH and boiled for 1 h at 100°C. After cooling, 1 ml of glacial acetic acid was added and the solution was made up to 10 ml by adding deionised water. Then, 1 ml of this solution was mixed on ice with 2 ml of anthrone solution (100 mg anthrone dissolved in 50 ml of concentrated H\(_2\)SO\(_4\)); this mixture was boiled for additional 10 min at 100°C and then cooled. Aliquots were taken in a microplate reader, and the absorbance was measured at 490 nm.

**Insulin content in pancreases**

Rats were killed after 28 d treatment with *S. platensis* (250 mg/kg), and the pancreatic tissues were dissected, weighed, homogenised and extracted in (10 ml) acid alcohol solution (23·5 % distilled water, 75 % ethanol and 1·5 % HCl 12 ms). After centrifugation, the supernatant samples were stored at −20°C. Pancreatic insulin level was determined using rat insulin ELISA Kit (Crystal Chem™).

**Chemical characterisation by reversed-phase HPLC**

Crude extract was re-dissolved in solvent A (0·12 % (v/v) trifluoroacetic acid (TFA)—water) and purified by reversed-phase HPLC. The prepared crude extract solution was injected in to a Vydac 218TP1022 (C-18) reversed-phase HPLC column (Grace) equilibrated with 0·12 % (v/v) TFA/water at a flow rate of 1·0 ml/min. The concentration of acetonitrile within the eluting solvent was expanded using linear gradients 0 to 20 % over 10 min and to 70 % over a period of 25 min. The wavelengths of 254 and 360 nm were used to measure the absorbance.

**Statistical analysis**

Statistical analyses were performed by using SPSS for windows (version 20). The results are represented as mean values with their standard errors. Data were analysed using repeated-measures ANOVA followed by Dunnett’s adjustment and unpaired *t* test where applicable. *P*<0·05 was considered as the level of significance.

**Results**

**Effects of Spirulina platensis on insulin secretion from clonal pancreatic β-cells (BRIN BD11)**

Fig. 2(a) and (b) shows the effects of ethanol extract and butanol fraction of *S. platensis* on insulin secretion from BRIN-BD11 cells. Alanine (10 ms) was used as a positive control. Both extract and fraction (1·6–5000 μg/ml) stimulated insulin release concentrations dependently compared with control (5·6 μg glucose). Higher concentrations (1000–5000 μg/ml) also induced insulin release but were associated with decreased cell viability. Further tests revealed that the insulinotropic effects of a non-toxic dose of *S. platensis* (40 μg/ml) were significantly enhanced in the presence of 16·7 μM glucose (*P*<0·001), isobutyl-methyl xanthine (*P*<0·001) and tolbutamide (*P*<0·001, Fig. 2(c) and (d)). The phosphodiesterase inhibitor isobutyl-methyl xanthine and tolbutamide were used to modulate the glucose-
Fig. 2. Effects of ethanol extract and butanol fraction of Spirulina platensis on insulin release from (a and b) BRIN-BD11 cells, (c and d) islets of Langerhans and (e–h) BRIN-BD11 cells in the presence of established stimulators or inhibitors of insulin secretion. Values are means with their standard errors, n 8 and 4 for insulin release. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with 5.6 and 16.7 mM glucose alone. † P < 0.05, †† P < 0.01 and ††† P < 0.001 compared with 5.6 mM glucose in the presence of the extract or fraction. ‡ P < 0.05, ‡‡ P < 0.01, ‡‡‡ P < 0.001 compared with respective incubation in the absence of the extract or fraction. (a) 5.6 mM glucose; 5.6 mM glucose + butanol fraction (μg/ml). (b) 5.6 mM glucose; 5.6 mM glucose + 10 mM alanine; 5.6 mM glucose + butanol fraction (μg/ml). (c) 5.6 mM glucose; 5.6 mM glucose; 10 mM alanine; 16.7 mM glucose + glucagon-like peptide 1 (μM); 16.7 mM glucose + ethanol extract (μg/ml). (d) 1.4 mM glucose; 5.6 mM glucose; 10 mM alanine; 16.7 mM glucose + glucagon-like peptide 1 (μM); 16.7 mM glucose + butanol fraction (μg/ml). (e) Glucose alone; 5.6 mM glucose + ethanol extract (40 μg/ml). (f) Glucose alone; 5.6 mM glucose + butanol fraction (40 μg/ml). (g) Glucose (5.6 mM); 5.6 mM glucose + ethanol extract (40 μg/ml). (h) 5.6 mM glucose; 5.6 mM glucose + butanol fraction (40 μg/ml).
Fig. 3. Effects of butanol fraction of *Spirulina platensis* on insulin release from perfused rat pancreas in the (a) absence or (b) presence of theophylline (10 mM), (c) verapamil (50 μM) and (d) diazoxide (8 mM) at 11 mM glucose and (e) control group: arginine (19 mM) alone. Values are means with their standard errors, n 4. Pancreas was perfused (1 ml/min) with butanol fraction of *S. platensis* at a dose of 5 mg/ml in the presence or absence of theophylline (10 mM), verapamil (50 μM) and diazoxide (8 mM) at 11 mM glucose and control group: arginine (19 mM) alone. The glucose concentration was raised from the basal level of 2.8 mM (basal) to 11 mM. G, glucose, THEO, theophylline; BSP, butanol fraction of *S. platensis*.
Antidiabetic actions of *Spirulina platensis* 1027

induced cAMP production and insulin secretion. In contrast, the effects of both ethanol extract and butanol fraction of *S. platensis* were inhibited by 40–50% by diazoxide (P < 0.05) and verapamil (P < 0.01, Fig. 2(c) and (f)). Both diazoxide, a K<sub>ATP</sub> channel opener and verapamil, voltage-gated Ca channel blocker inhibited pancreatic insulin secretion by reducing intracellular Ca<sup>2+</sup> influx. The ethanol extract and butanol fraction also maintained an ability to increase insulin secretion in cells depolarised with 30 mM KCl (P < 0.01, Fig. 2(c) and (f)). Absence of Ca<sup>2+</sup> (Fig. 2(g) and (h)) significantly inhibited but did not totally abolish insulin secretion induced by *S. platensis*.

**Effects of Spirulina platensis on insulin secretion from isolated islets**

The ethanol extract and butanol fraction significantly increased insulin secretion from isolated mouse islets compared with 16.7 mM glucose alone (P < 0.05–P < 0.001; Fig. 2(c) and (d)). Increasing the concentrations from 25 to 200 μg/ml resulted in 2- and 5-fold increase in insulin release compared with control (16.7 mM glucose); glucagon-like peptide 1 (10<sup>–6</sup> and 10<sup>–8</sup> M) and alanine (10 μM) were used in this experiment as positive control (Fig. 2(c) and (d)).

**Effects of Spirulina platensis on insulin secretion from perfused pancreas**

In a pilot study, the pancreas retained insulin secretory capacity during 70 min with exposure to glucose and arginine (Fig. 3(c)). Butanol fraction of *S. platensis* produced a significant (P < 0.001) biphasic increase in insulin release with a 20-fold elevation above the basal level (2.8 μu) (Fig. 3(a)). Subsequent exposure for 10 min to 11 mM glucose caused a sharp rise of insulin release from the basal level of 0.05–0.01 ng/ml to a peak of 2-4–1.5 ng/ml (P < 0.001). After adding butanol fraction to 11 mM glucose, a further enhancement in insulin release was noted (Fig. 3(a)), which opposed the decline in insulin release under the continuous exposure to 11 mM glucose alone. Theophylline (10 μM) is a methylxanthine derivative that inhibits cyclic nucleotide phosphodiesterase and increases the intracellular cyclic 3',5'-AMP level. Addition of theophylline (10 μM) to butanol fraction increased insulin secretion further (Fig. 3(b)). As shown in Fig. 3(c) and (d), perfusion in the presence of verapamil and diazoxide at 11 mM glucose decreased insulin releasing activity of the butanol fraction by 20–30%.

**Effects of Spirulina platensis on membrane potential and intracellular calcium ([Ca<sup>2+</sup>]i) in the clonal BRIN-BD11 cell line**

The ethanol extract and butanol fraction of *S. platensis* increased membrane potential and intracellular Ca ([Ca<sup>2+</sup>]i) at the presence of 5.6 mM glucose (P < 0.05; Fig. 4(a–h)) as compared with control (5.6 mM glucose alone). KCl (30 μM) and alanine (10 μM) were used as positive controls in this experiment.

**Effects of Spirulina platensis on dipeptidyl peptidase IV activity in vitro**

The butanol fraction significantly (P < 0.05, P < 0.01 and P < 0.001) inhibited the liberation of 7-amino-4-methylcoumarin, by 7–70% at concentrations of 200–5000 μg/ml (Fig. 5(f)). Sitagliptin, as an established DPP-IV inhibitor, reduced DPP-IV activity by 10–97% (P < 0.05, P < 0.01 and P < 0.001; Fig. 5(e)) at concentrations between 16 × 10<sup>–4</sup> to 5 μM.

**Effects of Spirulina platensis on unabsorbed sucrose content in the gut**

At 1 h following sucrose load (2.5 g/kg b.w.), a significant (P < 0.05–0.01) amount of sucrose was measured in the stomach and the upper, middle, lower and large intestine (Fig. 6(a–f)). An extensive (P < 0.01) amount of sucrose found in the stomach, upper and middle intestine at 30 min, while at 2 h (P < 0.05), increased amounts of unabsorbed sucrose were measured in caecum and lower intestine. The administration of butanol fraction (250 mg/kg b.w.) with sucrose reduced sucrose absorption significantly (P < 0.01) after 30 min and up to 2 h (Fig. 6). At 4 h, sucrose content was almost nil throughout the GI tract, although a small fraction remained in the caecum and lower intestine, indicating rapid hydrolysis and absorption of sucrose in the upper part of the intestine (Fig. 6).

**Effects of Spirulina platensis on intestinal disaccharidase activity and gastrointestinal motility**

Butanol fraction of *S. platensis* (250 mg/kg b.w.) did not affect disaccharidase enzyme activity (Fig. 7(c)). However, this fraction significantly promoted gastrointestinal motility (P < 0.05, Fig. 7(d)).

**Acute and chronic effects of Spirulina platensis on glucose homoeostasis in type 2 diabetic rats**

Oral administration of butanol fraction of *S. platensis* (250 mg/kg b.w.) together with glucose (2.5 g/kg b.w.) improved glucose tolerance at 30 and 60 min (P < 0.01–P < 0.05) in T2DM rats (Fig. 5(a) and (b)). In addition, *S. platensis* (250 mg/kg b.w.) treatment lowered serum glucose significantly after sucrose load (P < 0.05; Fig. 5(c) and (d)) at 60 and 120 min in T2DM rats. Furthermore, twice daily oral administration of the butanol fraction of *S. platensis* (250 mg/kg b.w.) for 28 d significantly lowered serum glucose levels (P < 0.05) and increased serum insulin level (P < 0.05) compared with controls (Table 1). Pancreatic insulin and liver glycogen were increased (P < 0.05) as shown in Table 1. Measurement of lipid profile showed that the butanol fraction of *S. platensis* (250 mg/kg b.w.) increased HDL, while the LDL and total cholesterol were significantly decreased (P < 0.05–0.01; Table 1).

**Chemical characterisation by reversed-phase HPLC**

The phytochemical screening of butanol fraction by HPLC (Fig. 8) revealed the presence of β-carotene, catechin and some
other previously identified compounds in *S. platensis* such as zeaxanthin, astaxanthin, *p*-coumaric acid and apigenin\(^{38,39}\). The concentrations of nutritional chemical characterisation of *S. platensis* are listed in Table 2.

**Discussion**

*S. platensis* has been reported recently to exhibit antihyperglycaemic effects, but the mechanism of action was not elucidated\(^{23–25}\). This study has examined the insulinotropic effects of *S. platensis*
using the perfused rat pancreas, isolated mouse islets and the clonal BRIN-BD11 β-cell line. The results suggest that the anti-hyperglycaemic effects are partly mediated through stimulating the insulin secretion from pancreatic β-cells(27), which is further supported by observation of incremental increases in serum and pancreatic insulin after 28 d of chronic treatment.

Both the ethanol extract and butanol fraction dose-dependently enhanced insulin release from isolated islets and clonal BRIN-BD11 cells. The butanol fraction was more insulinotropic than the ethanol extract. Likewise, the butanol fraction exerted substantial insulin release from perfused rat pancreas. Non-toxic concentrations of *S. platensis* were used to examine mechanisms underlying stimulation of insulin secretion in the absence and presence of known modulators of β-cell function. Sulfonylureas are known to act by closing K<sub>ATP</sub> channels, depolarising the plasma membrane, as induced by 30 mM KCl, and stimulating Ca<sup>2+</sup> entry by activation of voltage-dependent Ca channels(26,40). *S. platensis* stimulated insulin release enhanced by tolbutamide and KCl (30 mM), suggesting its ability to potentiate insulin secretion via other pathways such as the adenylate cyclase/cAMP or the phosphatidylinositol pathway, or as a direct effect on exocytosis(26).

*S. platensis* also clearly stimulated β-cells via its effects on Ca<sup>2+</sup> ion channels. Thus, diazoxide, a K<sub>ATP</sub>-channel opener(41), inhibited the insulin-releasing effects of both the extract and fraction. This suggests that *S. platensis* closes K<sub>ATP</sub> channels to induce insulinotropic action. Furthermore, the L-type voltage-dependent Ca<sup>2+</sup> channel blocker, verapamil(42), also reduced the insulin-releasing effects of *S. platensis*. This suggests

Fig. 5. Effects of butanol fraction of *Spirulina platensis* on (a and b) glucose tolerance (GTT), (c and d) serum glucose after sucrose load (SGASL) in type 2 diabetic rats and (e and f) DPP-IV activity in vitro. Rats were fasted for 12 and 24 h and administered glucose or sucrose solution (2.5 g/kg body weight) by oral administration in presence or absence of butanol fraction of *S. platensis* (250 mg/kg body weight). Sitagliptin was used as established DPP-IV inhibitor. Values are means with their standard errors represented by vertical bars (n 6, for GTT and SGASL and n 3 for DPP-IV). * P < 0.05, ** P < 0.01 and *** P < 0.001 compared with control. (a and c) Control; butanol fraction (250 mg/kg). (b and d) Control; butanol fraction (250 mg/kg). (e) Control; sitagliptin (µM). (f) Control; butanol fraction (µg/ml).
a dependency on Ca\(^{2+}\) channel to induce insulin release. Similar intracellular Ca\(^{2+}\) dependency was found in BRIN-BD11 cells, where \textit{S. platensis} increased insulin release, which was inhibited by the L-channel blocker verapamil. Furthermore, studies with BRIN BD11 cells showed \textit{S. platensis} induced membrane depolarisation and increased [Ca\(^{2+}\)]\(_i\).

The insulin-releasing effects of \textit{S. platensis} were also markedly increased by the phosphodiesterase inhibitors isobutyl-methyl xanthine and theophylline implicating involvement of the cAMP pathway\(^{(43)}\). Recent studies have shown that use of \textit{S. platensis} in asthma as adjunct therapy has improved the condition significantly\(^{(44)}\). The anti-asthmatic actions have been attributed to elevation of cAMP in bronchial smooth muscle cells, promoting airway relaxation and blocking replication of smooth muscle cells\(^{(45)}\). Overall, these results indicate that the polar solvents ethanol and butanol contain active molecules of \textit{S. platensis} that exert multiple effects on the \(\beta\)-cells mediated most importantly via ion channels.

DPP-IV is an enzyme that metabolises incretin hormones and as a result terminate the insulin-releasing and glucose-lowering actions of both glucagon-like peptide 1 and glucose-dependent insulino tropic polypeptide\(^{(46)}\). DPP-IV inhibitors have been developed to enhance endogenous incretin action and treat T2DM\(^{(47)}\). The two incretin hormones have been shown to have multiple action by increasing pancreatic insulin secretion and reducing glucagon secretion\(^{(46)}\). In the present study, \textit{S. platensis} significantly \((P < 0.05, P < 0.01\) and \(P < 0.001)\) inhibited DPP-IV

---

**Fig. 6.** Effects of butanol fraction of \textit{Spirulina platensis} on (a–f) gastrointestinal sucrose content after oral sucrose loading in type 2 diabetic rats. Type 2 diabetic rats were fasted for 24 h prior to the oral administration of sucrose solution (2.5 g/kg body weight) in the presence (treated group) or absence of (control group) butanol fraction of \textit{S. platensis} (250 mg/kg body weight). Values are means with their standard errors represented by vertical bars \((n 6)\). * \(P < 0.05\) and ** \(P < 0.01\) compared with type 2 diabetic control rats. (a–f) □ Control; butanol fraction (250 mg/kg).
enzyme activity, indicating that butanol fraction can enhance endogenous glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide activity. A recent study has shown that flavonol glycosides from the seeds of *Lens culinaris* Medikus (Fabaceae) inhibited DPP-IV enzyme activity in the dose-dependent manner (48). Therefore, it is anticipated that the same phytochemical constituents of *S. platensis* may be responsible for the observed DPP-IV inhibitory activity effect.

Administration of *S. platensis* significantly lowered blood glucose and improved glucose tolerance in T2DM rats. The butanol fraction also significantly inhibited glucose absorption during gut perfusion. As anticipated, significant amounts of unabsorbed glucose were found in the gut contents of control rats (Fig. 7a).

**Table 1.** Long-term effects of the butanol fraction of *Spirulina platensis* on blood glucose, plasma insulin, pancreatic insulin content and other parameters in type 2 diabetic rats after a 28-d study† (n = 8) (Mean values with their standard errors)

| Parameters               | 0 d                   | 28 d                   |
|--------------------------|-----------------------|------------------------|
|                          | Control | Butanol fraction | Control | Butanol fraction | Control | Butanol fraction |
| Glucose (mmol/l)         | Mean    | SEM        | Mean    | SEM        | Mean    | SEM        |
|                          | 9.71    | 1.41       | 9.53    | 1.27       | 9.67    | 1.45       |
| Plasma insulin (ng/ml)   | 0.47    | 0.19       | 0.48    | 0.29       | 0.46    | 0.18       |
| Pancreatic insulin (nmol/g) | –      | –         | 0.81    | 0.15       | 0.67*   | 0.15       |
| Liver glycogen (g/100 g) | –      | –         | 1.46    | 0.22       | 1.10*   | 0.11       |
| Total cholesterol (mmol/l)| –      | –         | 3.53    | 0.20       | 2.60*   | 0.12       |
| HDL (mmol/l)             | –      | –         | 2.41    | 0.15       | 3.15*   | 0.12       |
| LDL (mmol/l)             | –      | –         | 2.05    | 0.23       | 0.75**  | 0.16       |

*P* < 0.05 and **P** < 0.01 compared with type 2 diabetic control rats.
† Butanol fraction of *S. platensis* (250 mg/kg body weight) or only saline (control) was administered orally to rats for 28 d.
sucrose were found in postprandial state throughout the gut. This postprandial effect may be related to the interference of intestinal glucose absorption. The butanol fraction of *S. platensis* did not inhibit intestinal disaccharidase enzyme activity, and thus inhibition of digestion of carbohydrate is not involved in its mechanism of antihyperglycaemic action. However, increased GI motility, examined using BaSO4 milk, may inhibit carbohydrate absorption in the gut. Dietary fibres reduce post-prandial food transit time in the GI tract; thus, shorter time is available for the carbohydrate absorption, and therefore postprandial hyperglycaemia is reduced. High sucrose content in the GI tract indicates reduced sucrose digestion. As a result, a significantly higher concentration of sucrose reaches to the large intestine and cecum and is excreted. *S. platensis* reduced postprandial sucrose absorption and enhanced GI motility, possibly by forming glucose–fibre complexes that reduce post prandial transit time or gastric emptying time.

A recent study using *S. platensis* reported potential protective activity against fat induced apoptosis and decreasing intestinal cholesterol absorption. However, in the present chronic study, administration of butanol fraction of *S. platensis* for 28 d in type 2 diabetic rats significantly increased liver glycogen content and HDL, while it reduced LDL substantially. Interestingly, chronic treatment also enhanced plasma insulin and pancreatic insulin content in type 2 diabetic rats. Therefore, the stimulation of insulin release from β-cells as well as insulin action is possibly co-related with the improvement of hepatic glucose uptake.

The phytochemical screening of *S. platensis* using reversed-phase HPLC revealed the presence of several phenolic acids like p-coumaric acid and other bioactive molecules such as pheophytin A, catechin, zeaxanthin, astaxanthin, apigenin and carotenoid pigments including β-carotene. This composition is in general agreement with the previous research. Recent studies also claim that these compounds have antioxidant properties, trigger insulin secretion and have antihyperglycaemic activity.

In conclusion, this study has shown that ethanol extract of *S. platensis* and its butanol fraction exert prominent stimulatory.

---

Table 2. Major compounds identified by reversed-phase-HPLC of the butanol fraction of *Spirulina platensis*

| Peaks | Compounds        | RT (min) | Concentration (μg/ml) |
|-------|------------------|----------|-----------------------|
| 1     | Siphonein        | 10·3     | 20·6                  |
| 2     | Zeaxanthin       | 12·6     | 30·5                  |
| 3     | Astaxanthin      | 13·0     | 17·8                  |
| 4     | Unidentified carotenoids | 15·3 | 122·4                 |
| 5     | Catechin         | 23·5     | 15·6                  |
| 6     | Pheophytin A     | 26·2     | 15·6                  |
| 7     | p-Coumaric acid  | 29·0     | 51·3                  |
| 8     | β-Carotene       | 30·8     | 22·1                  |
| 9     | Apigenin         | 32·4     | 29·7                  |

RT, retention time.
effects on insulin secretion from β-cells via physiological pathways. In vivo studies in T2DM rats indicate that the butanol fraction decreased blood glucose, increased gut motility, reduced glucose absorption in GIT and improved both plasma and pancreatic insulin levels. *S. platensis* contains important phytocom- micals and valuable micro/macronutrients, consistent with the use of this microalgae as a prophylactic or dietary supplement in the treatment of diabetes.

Acknowledgements

The authors would like to thank the School of Biomedical Sciences and members of the Diabetes Research Group for providing access to their laboratory and the use of facilities to carry out this research.

The present study was supported by the Ulster University Strategic Research Funding and award of Vice Chancellor’s research studentship to P. A.

Y. H. A. A.W. and P. R. F. were responsible for the conception and design of research and also contributed equally to the supervision of the study. P. A., J. M. A. H. and S. A. performed the experiments. P. A. and S. A. analysed the data; P. A. and J. M. A. H. interpreted the results of experiments; P. A. prepared the figures; P. A. and S. A. drafted the manuscript; Y. H. A. A. W., P. R. F. and P.A. edited the revised manuscript; all authors approved the final version of the manuscript.

The authors declare that there are no conflicts of interest.

References

1. Brand-Miller J, McMillan-Price J, Steinbeck K, et al. (2009) Dietary glycemic index: health implications. *J Am Coll Nutr* **28**, 4465–4498.
2. Peters SA, Huxley RR & Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 958,507 individuals and 28,203 coronary events. *Diabetologia* **57**, 1542–1551.
3. Azzoo SH, Chattopadhyay K, Banerjee S, et al. (2018) Synergistic improved efficacy of *Gymnadenia orchis* seed, Sapel and pumpkin seed on induced diabetic complications. *Diabetes Res Clin Pract* **146**, 278–288.
4. Whitmer RA, Karter AJ, Yaffe K, et al. (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. *JAMA* **301**, 1565–1572.
5. Sims R & Hernandez C (2002) Treatment of diabetes mellitus: general goals, and clinical practice management. *Rev Esp Cardiol* **55**, 845–860.
6. Ghadge AA & Kuvalekar AA (2017) Controversy of oral hypoglycemic agents in type 2 diabetes mellitus: novel move towards combination therapies. *Diabetes Metab Syndr* **11**, S5–S13.
7. Stein SA, Lamos EM & Davis SN (2013) A review of the efficacy and safety of oral antidiabetic drugs. *Expert Opin Drug Saf* **12**, 153–175.
8. Singh A & Dwivedi S (2017) Study of adverse drug reactions in patients with diabetes attending a tertiary care hospital in New Delhi, India. *Indian J Med Res* **145**, 247–249.
9. Naja F, Alameddine M, Itani L, et al. (2015) The use of complementary and alternative medicine among Lebanese adults: results from a national survey. *Evid Based Complement Alternat Med* **2015**, 682597–682597.
10. Medagama AB, Bandara R, Abeysekera RA, et al. (2014) Use of Complementary and Alternative Medicines (CAMs) among type 2 diabetes patients in Sri Lanka: a cross sectional survey. *BMJ Complement Altern Med* **14**, 574.
11. Lunyera J, Wang D, Maro V, et al. (2016) Traditional medicine practices among community members with diabetes mellitus in Northern Tanzania: an ethnomedical survey. *BMJ Complement Altern Med* **16**, 282–282.
12. Jung M, Park M, Lee HC, et al. (2006) Antidiabetic agents from medicinal plants. *Curr Med Chem* **13**, 1203–1218.
13. Ji C, Han J, Zhang J, et al. (2018) Omics-prediction of bioactive peptides from the edible cyanobacterium *Arthrospira platensis* proteome. *J Sci Food Agric* **98**, 984–990.
14. Ibanez E & Cifuentes A (2013) Benefits of using algae as natural sources of functional ingredients. *J Sci Food Agric* **93**, 703–709.
15. Shahidi F & Ambigaipalan P (2015) Novel functional food ingredients from marine sources. *Curr Opin Food Sci* **2**, 123–129.
16. Sheih IC, Fang TJ, Wu TK, et al. (2010) Anticancer and antiinflammatory activities of the peptide fraction from algae protein waste. *J Agric Food Chem* **58**, 1202–1207.
17. Vo T-S, Ryu B & Kim S-R (2013) Purification of novel anti-inflammatory peptides from enzymatic hydrolysate of the edible microalgal *Spirulina maxima*. *J Funct Foods* **5**, 1336–1346.
18. Samarakoon KW, O’Nam K, Ko J-Y, et al. (2013) Purification and identification of novel angiotensin-1 converting enzyme (ACE) inhibitory peptides from cultured marine microalgae (*Nannochloropsis oculata*) protein hydrolysate. *J Appl Physiol* **125**, 1595–1606.
19. Pankaj PP (2015) Efficacy of *Spirulina platensis* in improvement of the reproductive performance and easing teratogenicity in hyperglycemic albino mice. *Indian J Pharmacol* **47**, 430–435.
20. Hosseini SM, Khorost-Vidarani K & Mozafari MR (2013) Nutritional and medical applications of spirulina microalgae. *Mini Rev Med Chem* **13**, 1251–1257.
21. Abdel-Daim MM, Abazadeh SM & Halawa SM (2013) Protective role of *Spirulina platensis* against acute dexamethasin-induced toxicity in rats. *PLOS ONE* **8**, e72991.
22. Deng R & Chow TJ (2010) Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae *Spirulina*. *Cardiovasc Ther* **28**, e35–e39.
23. Nasirian F, Mesbahi-Zadeh B, Maleki SA, et al. (2017) The effects of oral supplementation of *Spirulina platensis* microalgae on hematological parameters in streptozotocin-induced diabetic rats. *Am J Transl Res* **9**, 5238–5244.
24. Nasirian F, Dadkhah M, Moradi-Kor N, et al. (2018) Effects of *Spirulina platensis* microalgae on antioxidant and anti-inflammatory factors in diabetic rats. *Diabetes Metab Syndr Obes* **11**, 375–380.
25. Hanman JM, Marenah L, Ali I, et al. (2006) Ocimum sanctum leaf extracts stimulate insulin secretion from perfused pancreas, isolated islets and clonal pancreatic beta-cells. *J Endocrinol* **189**, 127–136.
26. Hanman JM, Marenah L, Ali I, et al. (2007) Insulin secretory actions of extracts of Asparagus racemosus root in perfused pancreas, isolated islets and clonal pancreatic beta-cells. *J Endocrinol* **192**, 159–168.
27. Flatt PR & Bailey CJ (1981) Abnormal plasma glucose and insul- lin responses in heterozygous lean (ob/+). *Diabetologia* **20**, 573–577.
29. Giroix MH, Portha B, Kergoat M, et al. (1983) Glucose insensitivity and amino-acid hypersensitivity in insulin release in rats with non-insulin-dependent diabetes. A study with the perfused pancreas. *Diabetes* **32**, 445–451.

30. Abdel-Wahab YH, Marenah L, Flatt PR, et al. (2007) Insulin releasing properties of the temporin family of antimicrobial peptides. *Peptides* **Protein Pept Lett** **14**, 702–707.

31. Miguel JC, Patterson S, Abdel-Wahab YH, et al. (2004) Time-correlation between membrane depolarization and intracellular calcium in insulin secreting BRIN-BD11 cells: studies using FLIPR. *Cell Calcium* **36**, 43–50.

32. Chatterjee T (1993) *Handbook of Laboratory Mice and Rats*.

33. Swintosky J & Pogonowskawala E (1982) The in-situ rat gut technique. *Pharm Int*.

34. Goto Y, Yamada K, Ohyama T, et al. (2007) Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. *Eur J Pharmacol* **568**, 278–286.

35. Hanman JM, Ali L, Khaleque J, et al. (2012) Antihyperglycaemic activity of *Asparagus racemosus* roots is partly mediated by inhibition of carbohydrate digestion and absorption, and enhancement of cellular insulin action. *Br J Nutr* **107**, 1316–1323.

36. Goto Y, Yamada K, Ohyama T, et al. (1995) An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans. *Diabetes Res Clin Pract* **28**, 81–87.

37. Swintosky J & Pogonowskawala E (1982) The in-situ rat gut technique. *Pharm Int* **3**, 163–170.

38. Chatterjee T (1995) *Handbook of Laboratory Mice and Rats*. India: Department of Pharmaceutical Technology, Jadavpur University.

39. Vies JV (1954) Two methods for the determination of glycogen in liver. *Biochem J* **57**, 410–416.

40. Mendiola JA, Marin FR, Hernandez SF, et al. (2005) Characterization via liquid chromatography coupled to diode array detector and tandem mass spectrometry of supercritical fluid antioxidant extracts of *Spirulina platensis* microalga. *J Sep Sci* **28**, 1031–1038.

41. Moor VJA, Pieme CA, Biapa PCN, et al. (2016) Chemical composition of *Spirulina platensis* of nomayos-yaounde. *Annals Food Sci Technol* **17**, 524–528.

42. Boyd AE 3rd (1988) Sulfonylurea receptors, ion channels, and fruit flies. *Diabetes* **37**, 847–850.

43. Wang Y, Wang S, Harvat T, et al. (2015) Diazoxide, a K(ATP) channel opener, prevents ischemia-reperfusion injury in rodent pancreatic islets. *Cell Transplant* **24**, 25–36.

44. Weinhaus AJ, Poronnik P, Cook DI, et al. (1995) Insulin secretagogues, but not glucose, stimulate an increase in [Ca2+]i in the fetal rat β-cell. *Diabetes* **44**, 118–124.

45. Sharp GW (1979) The adenylate cyclase-cyclic AMP system in islets of Langerhans and its role in the control of insulin release. *Diabetologia* **16**, 287–296.

46. Manzon-Reyes LVLA & Andaya AG (2018) The effects of *Spirulina* (*Arthrospira platensis*) dietary supplement as an adjunct therapy for children aged 7–14 years old with asthma: A randomized - double blind placebo controlled clinical trial. *J Allergy Clinical Immunol* **141**, AB208.

47. Billington CK, Ojo OO, Penn RB et al. (2013) cAMP regulation of airway smooth muscle function. *Palm Pharmaco Ther* **26**, 112–120.

48. Singh AK (2014) Dipeptidyl peptidase-4 inhibitors: novel mechanism of actions. *Indian J Endocrino Metab* **18**, 753–759.

49. Godinho R, Mega C, Teixeira-de-Lemos E, et al. (2015) The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a “me too” or “the special one” antidiabetic class? *J Diabetes Res* **2015**, 28.

50. Kim BR, Kim HY, Choi I, et al. (2018) DPP-IV inhibitory potentials of flavonol glycosides isolated from the seeds of *Lens culinaris* *in vitro* and molecular docking analyses. *Molecules* **23**, 1998.

51. Burkitt DP, Walker ARP & Painter NS (1972) Effect of dietary fibre on stools and transit-times, and its role in the causation of disease. *Lancet* **300**, 1408–1411.

52. Holgate AM & Read NW (1983) Relationship between small bowel transit time and absorption of a solid meal. Influence of metoclopramide, magnesium sulfate, and lactulose. *Dig Dis Sci* **28**, 812–819.

53. Yigit F, Gurel-Gurevin E, Isbilen-Basok B, et al. (2015) Protective effect of *Spirulina platensis* against cell damage and apoptosis in hepatic tissue caused by high fat diet. *Biotech Histochem* **91**, 182–194.

54. Ku CS, Kim B, Pham TX, et al. (2015) Hypolipidemic effect of a blue-green alga (*Nostoc commune*) is attributed to its nonlipid fraction by decreasing intestinal cholesterol absorption in *C57BL/6J* Mice. *J Med Food* **18**, 1214–1222.

55. Sayahi M & Shirali S (2017) The antidiabetic and antioxidant potentials of flavonol glycosides isolated from the seeds of *Leaves culinaris*. *J Diabetes Res* **2015**, 445–451.

56. Ku CS, Kim B, Pham TX, et al. (2015) Hypolipidemic effect of a blue-green alga (*Nostoc commune*) is attributed to its nonlipid fraction by decreasing intestinal cholesterol absorption in *C57BL/6J* Mice. *J Med Food* **18**, 1214–1222.

57. Sayahi M & Shirali S (2017) The antidiabetic and antioxidant effects of carotenoids: a review. *Asian J Pharm Res Health Care* **9**, 186–191.

58. Mueller L & Boehm V (2011) Antioxidant activity of β-carotene compounds in different *in vitro* assays. *Molecules* **16**, 1055–1069.

59. Amalan V, Vijayakumar N, Indumathi D, et al. (2016) Antidiabetic and antihyperlipidemic activity of *p*-coumaric acid in diabetic rats, role of pancreatic GLUT 2. *In vitro* approach. *Biomed Pharmacother* **84**, 230–236.